Bianco Gabriele, Lombardo Donatella, Ricciardelli Guido, Boattini Matteo, Comini Sara, Cavallo Rossana, Costa Cristina, Ambretti Simone
Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
Operative Unit of Microbiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Antibiotics (Basel). 2022 Oct 13;11(10):1404. doi: 10.3390/antibiotics11101404.
The aim of the study was to evaluate the EUCAST RAST method by extending analysis to 16−20 h reading time and performance with new β-lactam/β-lactamase inhibitor combinations. A total of 676 positive blood cultures (BCs) were enrolled. Results at 4 h, 6 h, 8 h and 16−20 h were interpreted according to bacterial species using EUCAST RAST breakpoints (version 5.1). For species for which no breakpoints were available, tentative breakpoints were used. Categorical agreement with the Microscan microdilution system was analysed. Among the 676 BCs enrolled, 641 were monomicrobial and were included in the analysis. Categorical agreement ranged from 98.9% at 4 h to 99.4% at 16−20 h. The rates of very major errors were 3.3%, 3.7% and 3.4% at 4 h, 6 h and 8 h, respectively, and decreased to 1% at 16−20 h (p < 0.001). The number of major errors was low for each reading time (0.2% and 0.4% at 4 h and 6 h, respectively, and 0.3% at both 8 h and 16−20 h). The proportions of results in the area of technical uncertainty were 9.9%, 5.9%, 5% and 5.2% for readings at 4 h, 6 h, 8 h and 16−20 h, respectively. Tentative breakpoints proposed for Enterobacterales other than E.coli/K.pneumoniae and coagulase-negative staphylococci showed overall performances comparable to those observed for E. coli/K. pneumoniae and S. aureus. In conclusion, EUCAST RAST has been shown to be reliable to determine microbial susceptibility to main antimicrobials, including ceftazidime/avibactam and ceftolozane/tazobactam. A poorer performance was observed for certain species/antimicrobial agent combinations. The better performance observed at 16−20 h compared to the early readings may confer to the method greater potential for antimicrobial de-escalation interventions.
本研究的目的是通过将分析时间延长至16 - 20小时读数,并评估新型β-内酰胺/β-内酰胺酶抑制剂组合的性能,来评价欧洲抗菌药物敏感性试验委员会(EUCAST)快速抗菌药物敏感性试验(RAST)方法。共纳入676份阳性血培养标本。4小时、6小时、8小时和16 - 20小时的结果根据细菌种类,使用EUCAST RAST折点(第5.1版)进行判读。对于没有折点的菌种,使用暂定折点。分析与Microscan微量稀释系统的分类一致性。在纳入的676份血培养标本中,641份为单一微生物感染,纳入分析。分类一致性从4小时的98.9%到16 - 20小时的99.4%不等。4小时、6小时和8小时的极重大错误率分别为3.3%、3.7%和3.4%,在16 - 20小时降至1%(p < 0.001)。每个读数时间的重大错误数量都很低(4小时和6小时分别为0.2%和0.4%,8小时和16 - 20小时均为0.3%)。4小时、6小时、8小时和16 - 20小时读数时,技术不确定区域的结果比例分别为9.9%、5.9%、5%和5.2%。针对除大肠埃希菌/肺炎克雷伯菌以外的肠杆菌科细菌和凝固酶阴性葡萄球菌提出的暂定折点,总体性能与大肠埃希菌/肺炎克雷伯菌和金黄色葡萄球菌的观察结果相当。总之,已证明EUCAST RAST在确定微生物对包括头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦在内的主要抗菌药物的敏感性方面是可靠的。对于某些菌种/抗菌药物组合,观察到性能较差。与早期读数相比,在16 - 20小时观察到的更好性能可能使该方法在抗菌药物降阶梯干预方面具有更大潜力。